Clinical trial · Observational
Salvage Cryotherapy in Recurrent Prostate Cancer
A Prospective Multicenter Registry of Salvage Cryotherapy in Recurrent Prostate Cancer Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Study was ended due to low enrollment
Summary
Brief summary (as posted)
To provide a systemic, uniform and user-friendly tool for collection of data on prostate cancer salvage cryotherapy in a multicenter setting. The goal is to learn more about the short and long term efficacy and safety of this procedure. Ultimately the data analysis will serve as a robust guidance instrument for improving upon the utilization of this procedure for the treatment of patients with recurrent (LRD) prostate cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Recurrent Prostate Cancer | Malignant Prostate Neoplasm | CURATED_BROADER | 0.78 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Cryoablation / Cryotherapy | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Observational
- description
- Patients with locally recurrent prostate cancer that have chosen salvage cryotherapy
- interventionNames
- Procedure: Cryoablation / Cryotherapy
Primary outcomes (1)
- measure
- Biochemical failure after treatment (defined as nadir PSA value + 2 ng/dl documented in the postoperative period).
- timeFrame
- 3-6 months intervals during the first 2 years after the completion of the procedure and yearly thereafter unless is amended by the treating physician
Secondary outcomes (4)
- measure
- Percentage change in QoL scores (EPIC) if available
- timeFrame
- 3-6 months intervals during the first 2 years after the completion of the procedure and yearly thereafter unless is amended by the treating physician
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 30 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * Read \& understand informed consent related to this study including consenting and HIPPA authorization * Undergone salvage cryotherapy of the prostate for recurrent prostate cancer Exclusion Criteria: * Patients who underwent radical prostatectomy as their primary therapy or other significant surgery (except prostatic biopsy) * Patients with clinically confirmed distant metastasis (unless deemed beneficial by the treating physician) * Any previous major rectal surgery * Clinically significant lower urinary tract or rectal anomalies * Existing urethral, rectal, or bladder fistulae
References
Publications (0)
Data not yet available